The resounding therapeutic success of the GIPR/GLP-1R co-agonist, tirzepatide, has seen a resurgence of interest in GIPR modulation for the management of T2DM and obesity (Nauck & Müller 2023). This evidence concerns the gene GIPR and Obesity.